The global challenge of removing PFAS from drinking water and industrial sources continues to grow, with regulators and utilities seeking reliable, lower-cost solutions. BioLargo Inc. (BLGO:OTCQX) has reached a notable milestone with its Aqueous Electrostatic Concentrator technology.
BioLargo Inc. (BLGO:OTCQX) announced that its patented Aqueous Electrostatic Concentrator (AEC) has processed more than 2 million gallons of PFAS-contaminated water after more than six months of continuous commercial operation at the municipal drinking water facility in Lake Stockholm, New Jersey, according to an August 3 release. PFAS, or per- and polyfluoroalkyl substances, are synthetic chemicals known for their persistence in the environment and human body, often called forever chemicals because the carbon-fluorine bond resists breakdown.
Market Opportunity in PFAS Remediation
PFAS contamination affects thousands of sites across the United States. The Environmental Working Group's latest PFAS contamination map identifies 9,728 confirmed sites with detectable levels of the so-called forever chemicals across all 50 states, the District of Columbia, and four U.S. territories. According to the nonprofit, updated data from the U.S. Environmental Protection Agency found PFAS in 3,539 public water systems. Research estimates that about 176 million people live in communities where drinking water has tested positive for PFAS. The global PFAS treatment market size was estimated at US$2.8 billion in 2025 and is projected to grow from US$3 billion in 2026 to US$4.8 billion by 2033, at a CAGR of 7.1% from 2026 to 2033. North America held the largest revenue share of 41.9% in 2025.
Why BioLargo Stands Out
BioLargo's AEC system began operating in January 2026 at the Lake Stockholm facility and now serves as a commercial demonstration site. Since installation, the system has consistently reduced PFAS concentrations to levels below all applicable New Jersey Department of Environmental Protection standards and U.S. Environmental Protection Agency maximum contaminant limits. The installation also generates substantially less contaminated waste than traditional carbon filtration systems, which helps lower hazardous waste disposal costs for the municipality.
Both the NJDEP and the U.S. EPA continue to oversee and evaluate the AEC system through a 12-month monitoring program designed to verify that the technology consistently meets or exceeds regulatory standards. This real-world municipal installation under third-party oversight addresses a key requirement for utilities and engineers evaluating new treatment options.
Key Assets and Catalysts
The Lake Stockholm project highlights broader commercial opportunities for the AEC technology in treating industrial wastewater, landfill leachate, and contaminated groundwater. BioLargo continues to conduct bench-scale pilot projects with prospective municipal and industrial customers while expanding commercialization efforts, including its recently announced memorandum of understanding with global water treatment company Aquatech. CEO Dennis P. Calvert noted that Lake Stockholm serves as the launch pad for the Aquatech strategy, pairing the AEC with PFAS treatment and destruction capabilities beyond municipal drinking water.
BioLargo's portfolio also includes Clyra Medical Technologies, which is advancing a wound care platform centered on its patented Copper-Iodine Complex Solution (CICS), which it markets under the Clyrasept brand. Its flagship product, ViaCLYR, has received FDA 510(k) clearance as a wound irrigation solution for cleansing, irrigating, and debriding dermal wounds and burns. The clearance covers burns, pressure ulcers, diabetic and stasis ulcers, post-surgical wounds, and abrasions.
Industry Timing and Trends
Conventional treatment methods, such as granular activated carbon and ion exchange systems, often struggle to capture short-chain PFAS compounds and generate significant volumes of contaminated spent media that require hazardous waste disposal. BioLargo states that its AEC technology eliminates the need for granular activated carbon or single-use ion exchange resins while producing only a small volume of concentrated residual waste. At the Lake Stockholm facility, the system has lowered operating costs compared with conventional granular activated carbon treatment.
The global wound care market is expected to expand from US$22.22 billion in 2025 to US$30.48 billion by 2030, representing a 6.5% compound annual growth rate, according to MarketsandMarkets. Rising rates of chronic diseases, traumatic injuries, burns, and the healthcare demands of an aging population support this growth.
Analyst Views and Valuation
1Technical Analyst John Newell of John Newell & Associates highlighted BioLargo's healthcare progress through its majority-owned subsidiary, Clyra Medical Technologies, in a March 11 report for Streetwise Reports. Newell assigned the company a Speculative Buy rating, noting the methodical approach of validating technologies before partnering for commercialization. In a May 18 report, Oak Ridge Financial Analyst Richard Ryan reiterated his Buy rating, describing BioLargo's operating strategy as a hub and spoke format that diversifies risk through separate operating subsidiaries while maintaining meaningful ownership stakes.
Share Structure and Upcoming Events
About 14.07% of BioLargo is owned by insiders and management. 2About 0.04% is held by institutions with 13F-disclosed institutional holdings only. The rest, 85.89%, is retail. Its market cap is US$33.37 million, with about 320.88 million shares outstanding. It trades in a 52-week range of US$0.10 and US$0.23.
Streetwise Ownership Overview*
BioLargo Inc. (BLGO:OTCQX)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 03/21/07 | NMED:OTCQX | 25 | BLGO:OTCQX | 1 |
| 11/20/02 | NWAY:OTCQX | 1 | NMED:OTCQX | 1 |
| 08/15/01 | LACI:OTCQX | 1 | NWAY:OTCQX | 1 |
Key Investor Takeaways
- BioLargo's AEC system has treated more than 2 million gallons of PFAS-contaminated water at the Lake Stockholm, New Jersey municipal facility. BioLargo reports that its AEC system has reduced PFAS levels below applicable NJDEP and EPA limits.
- The technology produces substantially less contaminated waste than traditional carbon filtration, which can reduce hazardous waste disposal costs for municipalities.
- A 12-month monitoring program by NJDEP and the U.S. EPA continues to verify consistent performance, providing third-party data for prospective customers.
- BioLargo maintains a memorandum of understanding with Aquatech to expand the AEC technology beyond municipal drinking water into industrial and environmental applications.
- Clyra Medical Technologies holds FDA 510(k) clearance for its ViaCLYR wound irrigation solution and is negotiating pricing agreements with large U.S. health systems.
- Two analysts have issued Buy or Speculative Buy ratings, citing the company's measured approach to commercialization through strategic partnerships.
Common Questions from Investors
What has the AEC achieved at Lake Stockholm? The system has processed more than 2 million gallons of drinking water and reduced PFAS levels below all applicable NJDEP and EPA standards over six months of continuous operation.
How does the AEC differ from conventional PFAS treatment? BioLargo states that the AEC avoids granular activated carbon and single-use resins, produces only a small volume of concentrated waste, and has lowered operating costs at the New Jersey site compared with traditional methods.
What is the status of the Aquatech partnership? BioLargo has a memorandum of understanding with Aquatech to combine the AEC with Aquatech's PFAS treatment and destruction capabilities for broader commercial applications.
What is ViaCLYR and its regulatory status? ViaCLYR is Clyra's FDA 510(k)-cleared wound irrigation solution that maintains antimicrobial activity for up to 72 hours in laboratory testing while showing no observed cytotoxicity to healthy cells.
Testing at the Lake Stockholm facility will continue under the U.S. EPA monitoring program, and the company plans to release additional third-party performance data as it becomes available. Investors should review the latest regulatory filings and monitor progress on both the water treatment and wound care platforms.
| Want to be the first to know about interesting Cleantech, Technology and Special Situations investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
- Disclosure for the quote from the John Newell article published on March 11, 2026
- For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
- Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
John Newell Disclaimer
As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.
- Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
